215 related articles for article (PubMed ID: 11145223)
1. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Pharm Res; 2000 Oct; 17(10):1189-97. PubMed ID: 11145223
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
5. Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression.
Takara K; Sakaeda T; Tanigawara Y; Nishiguchi K; Ohmoto N; Horinouchi M; Komada F; Ohnishi N; Yokoyama T; Okumura K
Eur J Pharm Sci; 2002 Aug; 16(3):159-65. PubMed ID: 12128170
[TBL] [Abstract][Full Text] [Related]
6. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
[TBL] [Abstract][Full Text] [Related]
7. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Biol Pharm Bull; 1999 Dec; 22(12):1355-9. PubMed ID: 10746169
[TBL] [Abstract][Full Text] [Related]
9. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
10. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4.
Bhardwaj RK; Glaeser H; Becquemont L; Klotz U; Gupta SK; Fromm MF
J Pharmacol Exp Ther; 2002 Aug; 302(2):645-50. PubMed ID: 12130727
[TBL] [Abstract][Full Text] [Related]
11. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4.
Ohnishi A; Matsuo H; Yamada S; Takanaga H; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Br J Pharmacol; 2000 Jul; 130(6):1369-77. PubMed ID: 10903978
[TBL] [Abstract][Full Text] [Related]
12. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.
Sakaeda T; Iwaki K; Kakumoto M; Nishikawa M; Niwa T; Jin JS; Nakamura T; Nishiguchi K; Okamura N; Okumura K
J Pharm Pharmacol; 2005 Jun; 57(6):759-64. PubMed ID: 15969931
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine.
Ikemura N; Yamaori S; Kobayashi C; Kamijo S; Murayama N; Yamazaki H; Ohmori S
Chem Biol Interact; 2019 Jun; 306():1-9. PubMed ID: 30965050
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
Achira M; Suzuki H; Ito K; Sugiyama Y
AAPS PharmSci; 1999; 1(4):E18. PubMed ID: 11741214
[TBL] [Abstract][Full Text] [Related]
15. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
[TBL] [Abstract][Full Text] [Related]
16. Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport.
Takara K; Sakaeda T; Kakumoto M; Tanigawara Y; Kobayashi H; Okumura K; Ohnishi N; Yokoyama T
Oncol Res; 2009; 17(11-12):527-33. PubMed ID: 19806783
[TBL] [Abstract][Full Text] [Related]
17. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil.
Kakumoto M; Sakaeda T; Takara K; Nakamura T; Kita T; Yagami T; Kobayashi H; Okamura N; Okumura K
Cancer Sci; 2003 Jan; 94(1):81-6. PubMed ID: 12708479
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
19. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
20. Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
Baron JM; Goh LB; Yao D; Wolf CR; Friedberg T
J Pharmacol Exp Ther; 2001 Feb; 296(2):351-8. PubMed ID: 11160617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
